Q-VD-OPh as a Mitochondrial Apoptosis Probe

2026-09-08

Q-VD-OPh is a cell-permeable pan-caspase inhibitor for dissecting how mitochondrial remodeling connects to apoptotic execution. This guide uses LACTB biology to show how caspase inhibition can strengthen causal interpretation in apoptosis research without being mistaken for proof of upstream mitochondrial events.

Lysoptosis and Serpin Control of Cathepsin-Driven Death

2026-09-08

The reference study defines lysoptosis as a conserved lysosome-dependent cell death pathway in which lysosomal membrane permeabilization releases cathepsins that drive cytoplasmic proteolysis. By comparing serpin-deficient worm, mouse, and human epithelial models, it shows that intracellular serpins restrain this pathway and that cathepsin L is a major executioner.

Z-IETD-FMK: Caspase-8 Inhibition Guide

2026-09-07

Caspofungin: From Glucan Target to Translation

2026-09-07

Caspofungin is more than a conventional susceptibility-control compound: it is a mechanistically defined probe of fungal cell wall dependence. This thought-leadership guide connects glucan synthase inhibition with assay design, resistance interpretation, comparative antifungal development, and translational decision-making for Candida research.

Hagenia abyssinica Field Trials Against Biomphalaria

2026-09-05

This field study moves Hagenia abyssinica molluscicide research beyond laboratory screening by testing flower-derived fractions against Biomphalaria snails and evaluating acute toxicity in Nile tilapia. The results confirm snail-killing activity under small-scale field conditions but also show greater sensitivity in fish, emphasizing that efficacy and ecological safety must be assessed together.

Iptacopan (LNP023) Complement Assay Workflows

2026-09-04

Build more selective alternative-pathway experiments with Iptacopan (LNP023), from factor B enzyme testing to serum MAC and PNH hemolysis assays. This workflow-focused guide explains assay design, translational use in animal models, controls, and practical troubleshooting.

Iptacopan (LNP023) Workflows for Complement Research

2026-09-04

Build more interpretable complement activation research with Iptacopan (LNP023), from factor B target engagement to serum MAC formation and PNH hemolysis. This workflow-focused guide explains dose selection, orthogonal readouts, translational disease models, and practical troubleshooting.

Rucaparib (AG-014699) Workflows for DNA Repair

2026-09-03

Rucaparib (AG-014699) supports tunable PARP1 inhibition in DNA-damage, radiation, and cancer-cell assays. This workflow connects prostate cancer radiosensitization with a newer HCC model in which spliceosome regulation alters PARP inhibitor response, helping researchers design stronger controls and troubleshoot variable phenotypes.

Coumestrol: From ER Antagonism to RA Ferroptosis

2026-09-03

Coumestrol is more than a phytoestrogen estrogen receptor antagonist: emerging evidence connects its activity to PMAIP1-dependent ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. This thought-leadership analysis translates that finding into a practical framework for receptor attribution, exposure design, formulation control, and translational decision-making.

AZD1390 for Reliable ATM Assays

2026-09-02

Learn how AZD1390 (SKU B8328) can improve interpretation of ATM-dependent DNA damage, viability, proliferation, and radiosensitization experiments. This scenario-based guide connects product specifications with practical controls, dosing anchors, storage, and data-analysis decisions for cancer research.

CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer

2026-09-02

The 2024 reference study identifies Cdc2-like kinase 2 (CLK2) as a determinant of platinum resistance in ovarian cancer and links its activity to BRCA1 Ser1423 phosphorylation and DNA damage repair. Its combination of tissue profiling, functional assays, mechanistic analysis, and xenograft validation provides a framework for studying how repair signaling limits platinum-induced apoptosis.

Z-YVAD-FMK: Reading Mixed-Death Assays

2026-09-01

Z-YVAD-FMK is a cell-permeable caspase-1 inhibitor for dissecting inflammatory cell-death pathways. This article explains how to interpret its results in complex apoptosis, pyroptosis, inflammasome, and bystander-necroptosis models without confusing pathway modulation with proof of mechanism.

BIBR 1532: Selective Telomerase Inhibitor Guide

2026-09-01

BIBR 1532 is a non-nucleosidic telomerase inhibitor that targets the hTERT reverse transcriptase component and is reported to inhibit telomerase activity with an IC50 of 93 nM. Product information connects this activity with telomere shortening, cancer cell proliferation inhibition, and apoptosis-associated signaling in leukemia models.

Caspase-8 Fluorometric Assay Kit Workflow

2026-08-31

Translate treatment-induced caspase-8 activation into a quantitative fluorescence readout for apoptosis, pyroptosis, and drug-response studies. This workflow connects IETD-AFC substrate cleavage with orthogonal validation, helping researchers distinguish functional enzyme activation from protein accumulation.

JNJ-26481585 (Quisinostat) in Tumor Assays

2026-08-31

JNJ-26481585 (Quisinostat) combines potent HDAC inhibition with a practical workflow for measuring chromatin remodeling, apoptosis, proliferation, and resistance biology. Its use in TRIM21–ERK1/2 research creates a focused bridge between epigenetic modulation and drug-sensitization studies.